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Summary
Background In the face of rapidly changing data, a range of case fatality ratio estimates for coronavirus disease 2019 
(COVID-19) have been produced that differ substantially in magnitude. We aimed to provide robust estimates, 
accounting for censoring and ascertainment biases.
Methods We collected individual-case data for patients who died from COVID-19 in Hubei, mainland China 
(reported by national and provincial health commissions to Feb 8, 2020), and for cases outside of mainland China 
(from government or ministry of health websites and media reports for 37 countries, as well as Hong Kong and 
Macau, until Feb 25, 2020). These individual-case data were used to estimate the time between onset of symptoms 
and outcome (death or discharge from hospital). We next obtained age-stratified estimates of the case fatality ratio 
by relating the aggregate distribution of cases to the observed cumulative deaths in China, assuming a constant 
attack rate by age and adjusting for demography and age-based and location-based under-ascertainment. We also 
estimated the case fatality ratio from individual line-list data on 1334 cases identified outside of mainland China. 
Using data on the prevalence of PCR-confirmed cases in international residents repatriated from China, we 
obtained age-stratified estimates of the infection fatality ratio. Furthermore, data on age-stratified severity in a 
subset of 3665 cases from China were used to estimate the proportion of infected individuals who are likely to 
require hospitalisation.
Findings Using data on 24 deaths that occurred in mainland China and 165 recoveries outside of China, we estimated 
the mean duration from onset of symptoms to death to be 17·8 days (95% credible interval [CrI] 16·9–19·2) and to 
hospital discharge to be 24·7 days (22·9–28·1). In all laboratory confirmed and clinically diagnosed cases from 
mainland China (n=70 117), we estimated a crude case fatality ratio (adjusted for censoring) of 3·67% (95% CrI 
3·56–3·80). However, after further adjusting for demography and under-ascertainment, we obtained a best estimate 
of the case fatality ratio in China of 1·38% (1·23–1·53), with substantially higher ratios in older age groups 
(0·32% [0·27–0·38] in those aged <60 years vs 6·4% [5·7–7·2] in those aged ≥60 years), up to 13·4% (11·2–15·9) in 
those aged 80 years or older. Estimates of case fatality ratio from international cases stratified by age were consistent 
with those from China (parametric estimate 1·4% [0·4–3·5] in those aged <60 years [n=360] and 4·5% [1·8–11·1] in 
those aged ≥60 years [n=151]). Our estimated overall infection fatality ratio for China was 0·66% (0·39–1·33), with an 
increasing profile with age. Similarly, estimates of the proportion of infected individuals likely to be hospitalised 
increased with age up to a maximum of 18·4% (11·0–37·6) in those aged 80 years or older.
Interpretation These early estimates give an indication of the fatality ratio across the spectrum of COVID-19 disease 
and show a strong age gradient in risk of death.
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Introduction
As of March 25, 2020, 414 179 cases and 18 440 deaths due 
to coronavirus disease 2019 (COVID-19), caused by the 
novel severe acute respiratory syndrome corona virus 2 
(SARS-CoV-2), had been reported worldwide.1 The epide-
mic began in mainland China, with a geographical focus 
in the city of Wuhan, Hubei. However, on Feb 26, 2020, 
the rate of increase in cases became greater in the rest of 
the world than inside China. Substantial outbreaks are 
occurring in Italy (69 176 cases), the USA (51 914 cases), 
and Iran (24 811 cases), and geographical expansion of the 
epidemic continues.
Clinical studies of hospitalised patients have shown that, 
at onset of COVID-19, patients frequently show symptoms 
associated with viral pneumonia, most commonly fever, 
cough, sore throat, myalgia, and fatigue.2–6 The case defi-
nition adopted in China and elsewhere includes further 
stratification of cases as severe (defined as tachypnoea 
[≥30 breaths per min], oxygen saturation ≤93% at rest, or 
PaO2/FiO2 ratio <300 mm Hg) and critical (respiratory 
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failure requiring mechanical ventilation, septic shock, or 
other organ dysfunction or failure that requires intensive 
care).7 According to the report from the WHO–China Joint 
Mission on COVID-19, 80% of the 55 924 patients with 
laboratory-confirmed COVID-19 in China to Feb 20, 2020, 
had mild-to-moderate disease, including both non-
pneumonia and pneumonia cases, while 13·8% developed 
severe disease and 6·1% developed to a critical stage 
requiring intensive care.8 In a study of clinical progression 
in 1099 patients,4 those at highest risk for severe disease 
and death included people over the age of 60 years and 
those with underlying conditions, including hypertension, 
diabetes, cardio vascular disease, chronic respiratory 
disease, and cancer.
Assessing the severity of COVID-19 is crucial to 
determine the appropriateness of mitigation strategies 
and to enable planning for health-care needs as epidemics 
unfold. However, crude case fatality ratios obtained by 
dividing the number of deaths by the number of cases 
can be misleading.9,10 First, there can be a period of 
2–3 weeks between a person developing symptoms, the 
case subsequently being detected and reported, and 
observation of the final clinical outcome. During a 
growing epidemic, the final clinical outcome of most of 
the reported cases is typically unknown. Simply dividing 
the cumulative reported number of deaths by the cumu-
lative number of reported cases will therefore under-
estimate the true case fatality ratio early in an epidemic.9–11 
This effect was observed in past epidemics of respiratory 
pathogens, including severe acute respiratory syndrome 
(SARS)12 and H1N19 influenza, and as such is widely 
recognised. Thus, many of the estimates of the case 
fatality ratio that have been obtained to date for COVID-19 
correct for this effect.13–16 Additionally, however, during 
the exponential growth phase of an epidemic, the 
observed time lags between the onset of symptoms and 
outcome (recovery or death) are censored, and naive 
estimates of the observed times from symptom onset 
to outcome provide biased estimates of the actual dis-
tributions. Ignoring this effect tends to bias the estimated 
Research in context
Evidence before this study
We searched PubMed, medRxiv, bioRxiv, arXiv, SSRN, 
Research Square, Virological, and Wellcome Open Research for 
peer-reviewed articles, preprints, and research reports on the 
severity of coronavirus disease 2019 (COVID-19), using the 
search terms “coronavirus”, “2019-nCoV”, and similar terms, 
and “fatality”, up to March 6, 2020. Several studies have 
estimated the case fatality ratio (the percentage of individuals 
with symptomatic or confirmed disease who die from the 
disease) and infection fatality ratio (the percentage of all 
infected individuals who die from the disease, including those 
with mild disease) of COVID-19 using a range of different 
statistical and modelling methods. Studies done solely in 
hospitalised patients report the highest fatality ratios (8–28%), 
representing the outcome for the most severely ill patients. 
Estimates of the population-level case fatality ratio from all 
case reports are in the range of 2–8%. Estimates of the infection 
fatality ratio averaged across all age-groups range from 
0·2% to 1·6%, while estimates of the infection fatality ratio in 
the oldest age group (≥80 years) range from 8% to 36%. 
None of the identified studies had adjusted for differences in 
the denominator populations to obtain estimates that could be 
applied across populations. No other studies have estimated 
the proportion of infected individuals who will require 
hospitalisation.
Added value of this study
By synthesising data from across a range of surveillance settings, 
we obtained estimates of the age-stratified case fatality ratio 
and infection fatality ratio that take into account the different 
denominator populations in the datasets. Our underlying 
assumption, that attack rates (ie, the probability of becoming 
infected) do not vary substantially by age, is consistent with 
previous studies for respiratory infections. Under this 
assumption, differences in age patterns among cases in 
Wuhan versus those elsewhere in China would probably due to 
under-ascertainment of cases, given the different surveillance 
systems in place. Our results are consistent with this hypothesis, 
with cases in Wuhan seen in older individuals, who would have 
been identified through attendance at hospital, whereas cases 
elsewhere in China being younger overall, which would be 
explained by the policy of testing those with a travel history to 
Wuhan. After correcting for these biases, we found that 
estimates of the case fatality ratio from China are consistent 
with those obtained from early international cases. Our 
age-stratified estimates of the infection fatality ratio can be 
applied to any demography to give an estimate of the infection 
fatality ratio in older and younger populations. These estimates 
can be combined with estimates of the infection attack rate 
(approximately 80% for an unmitigated epidemic) to give rough 
projections of scale. Similarly, our estimates of the proportion of 
infections requiring hospitalisation can be combined with the 
infection attack rate to forecast health-care requirements.
Implications of all the available evidence
Our estimates of the case fatality ratio for COVID-19, although 
lower than some of the crude estimates made to date, are 
substantially higher than for recent influenza pandemics 
(eg, H1N1 influenza in 2009). With the rapid geographical 
spread observed to date, COVID-19 therefore represents a 
major global health threat in the coming weeks and months. 
Our estimate of the proportion of infected individuals requiring 
hospitalisation, when combined with likely infection attack 
rates (around 50–80%), show that even the most advanced 
health-care systems are likely to be overwhelmed. These 
estimates are therefore crucial to enable countries around 
the world to best prepare as the global pandemic continues 
to unfold.
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case fatality ratio downwards during the early growth 
phase of an epidemic.
Second, surveillance of a newly emerged pathogen is 
typically biased towards detecting clinically severe cases, 
especially at the start of an epidemic when diagnostic 
capacity is low (figure 1). Estimates of the case fatality 
ratio can thus be biased upwards until the extent of 
clinically milder disease is determined.9 Data from the 
epicentre of the outbreak in Wuhan have primarily been 
obtained through hospital surveillance and, thus, are 
likely to represent patients with moderate or severe 
illness, with atypical pneumonia or acute respiratory 
distress being used to define suspected cases eligible for 
testing.7 In these individuals, clinical outcomes are likely 
to be more severe, so any estimates of the case fatality 
ratio will be higher. Elsewhere in mainland China and 
the rest of the world, countries and administrative 
regions alert to the risk of infection being imported via 
travel initially instituted surveillance for COVID-19 with 
a broader set of clinical criteria for defining a suspected 
case. These criteria typically included a combination of 
symptoms (eg, cough and fever) combined with recent 
travel history to the affected region (Wuhan, or Hubei 
province)2,17. Such surveillance is likely to detect clinically 
mild cases but, by initially restricting testing to those 
with a travel history or link, might have missed other 
symptomatic cases.
Here we attempt to adjust for these biases in data 
sources to obtain estimates of the case fatality ratio 
(proportion of all cases that will eventually lead to death) 
and infection fatality ratio (the proportion of all infections 
that will eventually lead to death) using both individual-
level case report data and aggregate case and death 
counts from mainland China, from Hong Kong and 
Macau, and international case reports. By adjusting for 
both underlying demography and potential under-
ascertainment at different levels of the severity pyramid 
(figure 1), these estimates should be broadly applicable 
across a range of settings to inform health planning 
while more detailed case data accrue.
Methods
Individual-level data on early deaths from mainland 
China
We identified information on the characteristics of 
48 patients who died from COVID-19 in Hubei, reported 
by the National Health Commission and the Hubei 
Province Health Commission website up to Feb 8, 2020.
We recorded the following data elements, where avai-
lable: sex, age, date of symptom onset, date of hospi-
talisation, and date of death. Of the 48 cases, neither the 
date of symptom onset nor the date of report was 
available for 13 cases. We also removed eight cases with 
onset before Jan 1, 2020, or death before Jan 21, 2020, and 
three deaths after Jan 28, 2020, which were the dates 
consistent with reliable reporting of onset and death in 
this setting, respectively, considering the onset-to-death 
times (including early onsets creates a bias towards long 
onset-to-death times, reflecting under-ascertainment of 
deaths early on). This left 24 deaths, which we used to 
estimate the onset-to-death distribution.
Individual-level data on cases outside mainland China
We collated data on 2010 cases reported in 37 countries 
and two special administrative regions of China 
(Hong Kong and Macau), from government or ministry 
of health websites and media reports, until Feb 25, 2020. 
We recorded the following information where available: 
country or administrative region in which the case was 
detected, whether the infection was acquired in China or 
abroad, date of travel, date of symptom onset, date of 
hospitalisation, date of confirmation, date of recovery, 
and date of death. We used data from 165 recovered 
individuals with reported recovery dates and reported or 
imputed onset dates to estimate the onset-to-recovery 
distribution, after excluding 26 recoveries without appro-
priate information on dates of recovery, report, or locality. 
We used data on 1334 international cases to obtain 
estimates of the case fatality ratio, not including cases 
without dates of report.
Data on aggregate cases and deaths in mainland China
Data on 70 117 PCR-confirmed and clinically diagnosed 
cases by date of onset in Wuhan and elsewhere in China 
from Jan 1 to Feb 11, 2020, were extracted from the 
WHO–China Joint Mission report.8 Over this period a 
total of 1023 deaths were reported across China, with 
these data available disaggregated into 10-year age bands 
between 0–9 years and 70–79 years old, and a further age 
Figure 1: Spectrum of COVID-19 cases
At the top of the pyramid, those meeting the WHO case criteria for severe or critical cases are likely to be identified 
in the hospital setting, presenting with atypical viral pneumonia. These cases will have been identified in mainland 
China and among those categorised internationally as local transmission. Many more cases are likely to be 
symptomatic (ie, with fever, cough, or myalgia), but might not require hospitalisation. These cases will have been 
identified through links to international travel to high-risk areas and through contact-tracing of contacts of 
confirmed cases. They might also be identified through population surveillance of, for example, influenza-like 
illness. The bottom part of the pyramid represents mild (and possibly asymptomatic) cases. These cases might be 
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band for those aged 80 years or older.7 Using collated data 
on daily reported deaths obtained each day from the 
National Health Commission regional websites, we 
estimated that 74% of deaths occurred in Wuhan and 
the remainder outside Wuhan. Additionally, the most 
recent available cumulative estimates (March 3, 2020) of 
80 304 confirmed cases and 2946 deaths within China 
were extracted from the WHO COVID-19 Situation 
Report (number 43).1
An earlier (now withdrawn) preprint of a subset of 
these cases up to Jan 26, 2020 reported the age 
distribution of cases categorised by severity for 
3665 cases.18 Under the China case definition, a severe 
case is defined as tachypnoea (≥30 breaths per min) or 
oxygen saturation 93% or higher at rest, or PaO2/FiO2 
ratio less than 300 mm Hg.7 Assuming severe cases to 
require hospitalisation (as opposed to all of the patients 
who were hospitalised in China, some of whom will have 
been hospitalised to reduce onward transmission), we 
used the proportion of severe cases by age in these 
patients to estimate the proportion of cases and infections 
requiring hospitalisation.
Data on infection in repatriated international Wuhan 
residents
Data on infection prevalence in repatriated expatriates 
returning to their home countries were obtained from 
government or ministry of health websites and media 
reports. To match to the incidence reported in Wuhan on 
Jan 30, 2020, we used data from six flights that departed 
between Jan 30 and Feb 1, 2020, inclusive.
Data on cases and deaths on the Diamond Princess 
cruise ship
In early February 2020 a cruise liner named the 
Diamond Princess was quarantined after a disembarked 
passenger tested positive for the virus. Subsequently all 
3711 passengers on board were tested over the next 
month. We extracted data on the ages of passengers 
onboard on Feb 5, 2020, the dates of positive test reports, 
which were available for 657 out of 712 PCR-confirmed 
cases, and the dates of ten deaths among these cases 
from the reports of the Japan Ministry of Health, 
Labour and Welfare19 and inter national media.
Demographic data
Age-stratified population data for 2018 were obtained from 
the National Bureau of Statistics of China.20 According 
to these data, the population of Wuhan in 2018 was 
approximately 11 million people.
Statistical analysis overview
All analyses were done with R software (version 3.6.2), 
with Bayesian Marko-Chain Monte Carlo via the package 
drjacoby (version 1.0.0).21 Data and code are available 
online at GitHub.
Estimation of time intervals between symptom onset 
and outcome
In estimating time intervals between symptom onset 
and outcome, it was necessary to account for the fact 
that, during a growing epidemic, a higher proportion of 
the cases will have been infected recently (appendix 
p 7).Therefore, we re-parameterised a gamma model to 
account for exponential growth using a growth rate of 
0·14 per day, obtained from the early case onset data 
(appendix p 6). Using Bayesian methods, we fitted 
gamma distributions to the data on time from onset to 
death and onset to recovery, conditional on having 
observed the final outcome. Missing onset dates 
were imputed on the basis of dates of report, where 
available.
For the data and code used in 
this study see https://github.
com/mrc-ide/COVID19_CFR_
submission
See Online for appendix
Figure 2: Onset-to-death and onset-to-recovery distributions
(A) Onset-to-death data from 24 cases in mainland China early in the epidemic. (B) Onset-to-recovery data 
from 169 cases outside of mainland China. Red lines show the best fit (posterior mode) gamma distributions, 
uncorrected for epidemic growth, which are biased towards shorter durations. Blue lines show the same 
distributions corrected for epidemic growth. The black line (panel A) shows the posterior estimate of the 



































www.thelancet.com/infection   Vol 20   June 2020 673
Estimation of case fatality ratio, infection fatality ratio, 
and proportion hospitalised from aggregated case data
Estimates of the distribution of times from onset-to-
death were used to project the expected cumulative 
number of deaths given the onsets observed in Wuhan 
and outside Wuhan, assuming a uniform attack 
rate across age groups. Using the age-distribution of 
the population, we obtained an estimate of the 
expected number of infections in each age group. 
Under-ascertainment was estimated in and outside of 
Wuhan by comparing the number of observed cases by 
age to this expected distribution, assuming perfect 
ascertainment in the 50–59 age group as this group had 
the highest number of detected cases relative to 
population size. We also did a sensitivity analysis 
assuming a differential attack rate by age (appendix p 9). 
For Wuhan, we added scaling to account for further 
under-ascertainment compared with outside of Wuhan. 
These steps gave us the expected age-distribution of 
cases.
For a given onset-to-death distribution, we obtained a 
modelled estimate of the cumulative number of deaths 
by age under an age-dependent case fatality ratio (fitted 
relative to the case fatality ratio in the oldest age group, 
which represented the highest crude case fatality ratio). 
This estimate was compared with the observed deaths by 
age using a Poisson likelihood. These data were then 
jointly fitted alongside the most recent age-aggregated 
cumulative deaths and cases in mainland China. Given 
that the numbers of observed cases and deaths have 
dropped substantially following a peak in late January, 
the ratio of current cumulative cases to current number 
of deaths, once corrected for under-ascertainment, 
should provide a good estimate of the final case fatality 
ratio.11
To estimate the infection fatality ratio we fitted to data 
on infection prevalence from international Wuhan 
residents who were repatriated to their home countries. 
Our age-stratified case fatality ratio and infection fatality 
ratio model was jointly fitted to the case data and 
infection prevalence data with use of Bayesian methods, 
using our previous estimate of the onset-to-death 
distribution as a prior. Full mathematical details are 
provided in the appendix (p 8).
Assuming a uniform attack rate by age groups, we 
used the demography-adjusted under-ascertainment 
rates calculated above to obtain an estimate of the 
proportion of infected individuals who would require 
hospitalisation.
To independently validate our infection fatality ratio 
estimate, we analysed data from the outbreak on the 
Diamond Princess cruise liner taking the dates of reported 
positive tests as a proxy for onset date. We calculated 
the expected proportion of deaths observed until 
March 25, 2020, given the onset times and estimated 




Case fatality ratio Infection fatality ratio†
Crude Adjusted for censoring Adjusted for censoring, 
demography, and under-
ascertainment‡
Overall 1023 44 672 2·29% (2·15–2·43) 3·67% (3·56–3·80) 1·38% (1·23–1·53) 0·657% (0·389–1·33)
Age group, years
0–9 0 416 0·000% (0·000–0·883) 0·0954% (0·0110–1·34) 0·00260% (0·000312–0·0382) 0·00161% (0·000185–0·0249)
10–19 1 549 0·182% (0·00461–1·01) 0·352% (0·0663–1·74) 0·0148% (0·00288–0·0759) 0·00695% (0·00149–0·0502)
20–29 7 3619 0·193% (0·0778–0·398) 0·296% (0·158–0·662) 0·0600% (0·0317–0·132) 0·0309% (0·0138–0·0923)
30–39 18 7600 0·237% (0·140–0·374) 0·348% (0·241–0·577) 0·146% (0·103–0·255) 0·0844% (0·0408–0·185)
40–49 38 8571 0·443% (0·314–0·608) 0·711% (0·521–0·966) 0·295% (0·221–0·422) 0·161% (0·0764–0·323)
50–59 130 10 008 1·30% (1·09–1·54) 2·06% (1·74–2·43) 1·25% (1·03–1·55) 0·595% (0·344–1·28)
60–69 309 8583 3·60% (3·22–4·02) 5·79% (5·20–6·34) 3·99% (3·41–4·55) 1·93% (1·11–3·89)
70–79 312 3918 7·96% (7·13–8·86) 12·7% (11·5–13·9) 8·61% (7·48–9·99) 4·28% (2·45–8·44)
≥80 208 1408 14·8% (13·0–16·7) 23·3% (20·3–26·7) 13·4% (11·2–15·9) 7·80% (3·80–13·3)
Age category (binary), years
<60 194 30 763 0·631% (0·545–0·726) 1·01% (0·900–1·17) 0·318% (0·274–0·378) 0·145% (0·0883–0·317)
≥60 829 13 909 5·96% (5·57–6·37) 9·49% (9·11–9·95) 6·38% (5·70–7·17) 3·28% (1·82–6·18)
Crude case fatality ratios are presented as mean (95% confidence interval). All other fatality ratios are presented as posterior mode (95% credible interval). Estimates are shown 
to three significant figures. Cases and deaths are aggregate numbers reported from Jan 1 to Feb 11, 2020.8 Crude case fatality ratios are calculated as the number of deaths 
divided by the number of laboratory-confirmed cases. Our estimates also include clinically diagnosed cases (a scaling of 1·31 applied across all age-groups, as the breakdown by 
age was not reported for clinically diagnosed cases), which gives larger denominators and thus lower case fatality ratios than if only laboratory-confirmed cases were included. 
*Values do not include the clinically diagnosed cases included in our estimates. †Obtained by combining estimates of case fatality ratios with information on infection 
prevalence obtained from those returning home on repatriation flights. ‡Accounts for the underlying demography in Wuhan and elsewhere in China and corrects for under-
ascertainment.
Table 1: Estimates of case fatality ratio and infection fatality ratio obtained from aggregate time series of cases in mainland China
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Estimation of case fatality ratio from individual case data
We used parametric and non-parametric methods11,22 to 
estimate the case fatality ratio in cases reported outside 
of mainland China using individual-level data. Cases in 
which the outcome was unknown were treated as 
censored observations. For parametric and non-
parametric analyses, missing onset dates were multiply 
imputed using information on the onset-to-report 
distribution, and unreported recoveries were imputed 
using onset-to-outcome distributions and country 
summary data. The parametric models were fitted to the 
data using Bayesian methods (appendix p 12).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
In the subset of 24 deaths from COVID-19 that occurred 
in mainland China early in the epidemic, with correction 
for bias introduced by the growth of the epidemic, 
we estimated the mean time from onset to death to be 
18·8 days (95% credible interval [CrI] 15·7–49·7; 
figure 2) with a coefficient of variation of 0·45 (95% CrI 
0·29–0·54). With the small number of observations in 
these data and given that they were from early in the 
epidemic, we could not rule out many deaths occurring 
with longer times from onset to death, hence the high 
upper limit of the credible interval. However, given that 
Figure 3: Estimates of case fatality ratio by age, obtained from aggregate data from mainland China
(A) Age-distribution of cases in Wuhan and elsewhere in China. (B) Estimates of the case fatality ratio by age group, adjusted for demography and 
under-ascertainment. Boxes represent median (central horizontal line) and IQR, vertical lines represent 1·5 × IQR, and individual points represent any estimates 
outside of this range. (C) Estimated proportions of cases ascertained in the rest of China and in Wuhan relative to the 50–59 years age group elsewhere in China. 
Error bars represent 95% CrIs.
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the epidemic in China has since declined, our posterior 
estimate of the mean time from onset to death, informed 
by the analysis of aggregated data from China, is more 
precise (mean 17·8 days [16·9–19·2]; figure 2).
Using data on the outcomes of 169 cases reported 
outside of mainland China, we estimated a mean onset-
to-recovery time of 24·7 days (95% CrI 22·9–28·1) and 
coefficient of variation of 0·35 (0·31–0·39; figure 2). 
Both these onset-to-outcome estimates are consistent 
with a separate study in China.23
Case fatality ratios were estimated from aggregate data 
on cases and deaths in mainland China (table 1). A large 
proportion of the cases, including all of those early in the 
epidemic, were reported in Wuhan, where the local health 
system was quickly overwhelmed. As a result, the age 
distribution of cases reported in Wuhan differed to that in 
the rest of China (figure 3A). Reported cases in Wuhan 
were more frequent in older age groups, perhaps reflecting 
higher severity (and there fore prio ritisation for hospi-
talisation in Wuhan), while cases outside of Wuhan might 
also show a bias in terms of the relationship between 
age and travel. Adjusting for differences in underlying 
demography and assuming no overall difference in the 
attack rate by age, we estimated high under-ascertainment 
of cases in younger age groups both inside and outside of 
Wuhan (figure 3C, D). Furthermore, we estimated a higher 
level of under-ascertainment overall in Wuhan compared 
with outside of Wuhan (figure 3C). Accounting for this 
under-ascertainment, we estimated the highest case fatality 
ratio (13·4% [11·2–15·9%]) in the 80 years and older age 
group (figure 3B, table 1), with lower case fatality ratios 
associated with lower age groups, and the lowest in the 
0–9 years age group (0·00260% [0·000312–0·0382]).
In cases reported outside of mainland China, we 
estimated an overall modal case fatality ratio of 2·7% 
(95% CrI 1·4–4·7) using the parametric model (table 2). In 
those who reported travel to mainland China (and would 
therefore have been detected in the surveillance system), 
we estimated an overall modal case fatality ratio of 
1·1% (0·4–4·1), and in those without any reported travel to 
China (therefore detected either through contact tracing 
or through hospital surveillance), we estimated a case 
fatality ratio of 3·6% (1·9–7·2) using the parametric 
model. The estimated case fatality ratio was lower in those 
aged under 60 years of age (1·4% [0·4–3·5]) compared 
with those aged 60 years and over (4·5% [1·8–11·1]). 
Similar estimates were obtained using non-parametric 
methods (table 2).
In international Wuhan residents repatriated on 
six flights, we estimated a prevalence of infection of 0·87% 
(95% CI 0·32–1·9; six of 689). Adjusting for demography 
and under-ascertainment, we estimate an infection fatality 
ratio of 0·66% (95% CrI 0·39–1·33). As for the case 
fatality ratio, this is strongly age-dependent, with estimates 
rising steeply from age 50 years upwards (table 1). The 
demography-adjusted and under-ascertainment-adjusted 
proportion of infected individuals requiring hospitalisation 
ranges from 1·1% in the 20–29 years age group up to 
18·4% in those 80 years and older (table 3). Using these 
age-stratified infection fatality ratio estimates, we estimate 
the infection fatality ratio in the Diamond Princess 
population to be 2·9%. Given the delay from onset of 
symptoms to death, we would expect 97% of these deaths 
to have occurred by March 25, 2020, giving an estimate of 
the current infection fatality ratio of 2·8%, compared 
with the empirical estimate of  1·4% (95% CI 0·7–2·6; 
ten of 712).
Discussion
From an extensive analysis of data from different regions 
of the world, our best estimate at the current time for the 
Parametric Non-parametric
n Case fatality ratio n Case fatality ratio
Overall 585 2·7% (1·4–4·7) 1334 4·1% (2·1–7·8)
Travel versus local transmission
Travellers to 
mainland China
203 1·1% (0·4–4·1) 208 2·4% (0·6–8·5)
Local transmission 382 3·6% (1·9–7·2) 387 3·8% (1·7–8·2)
Age group, years
<60 360 1·4% (0·4–3·5) 449 1·5% (0·6–3·9)
≥60 151 4·5% (1·8–11·1) 181 12·8% (4·1–33·5)
Parametric estimates are presented as posterior mode (95% credible interval), and 
were obtained using the gamma-distributed estimates of onset-to-death and 
onset-to-recovery. Non-parametric estimates are presented as maximum 
likelihood estimate (95% confidence interval) and were obtained using a modified 
Kaplan-Meier method.11,23 Note that due to missing data on age and travel status, 
numbers in the stratified analysis are lower than for the overall analysis. In 
addition, the parametric method requires a correction for the epidemic growth 
rate, and these estimates were therefore obtained from the subset of data for 
which the travel or local transmission and age was known.
Table 2: Estimates of case fatality ratio obtained from individual-level 
data on cases identified outside of mainland China
Severe cases All cases Proportion of infected 
individuals hospitalised
0–9 years 0 13 0·00% (0·00–0·00)
10–19 years 1 50 0·0408% (0·0243–0·0832)
20–29 years 49 437 1·04% (0·622–2·13)
30–39 years 124 733 3·43% (2·04–7·00)
40–49 years 154 743 4·25% (2·53–8·68)
50–59 years 222 790 8·16% (4·86–16·7)
60–69 years 201 560 11·8% (7·01–24·0)
70–79 years 133 263 16·6% (9·87–33·8)
≥80 years 51 76 18·4% (11·0–37·6)
Proportions of infected individuals hospitalised are presented as posterior mode 
(95% credible interval) and are adjusted for under-ascertainment and corrected 
for demography. Estimates are shown to three signficant figures. We assumed, 
based on severity classification from a UK context, that cases defined as severe 
would be hospitalised.
Table 3: Estimates of the proportion of all infections that would lead 
to hospitalisation, obtained from a subset of cases reported in 
mainland China18
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case fatality ratio of COVID-19 in China is 1·38% 
(95% CrI 1·23–1·53). Although this value remains lower 
than estimates for other coronaviruses, including SARS24 
and Middle East respiratory syndrome (MERS),25 it is 
substantially higher than estimates from the 2009 H1N1 
influenza pandemic.26,27 Our estimate of an infection 
fatality ratio of 0·66% in China was informed by PCR 
testing of international Wuhan residents returning on 
repatriation flights. This value was consistent with the 
infection fatality ratio observed in passengers on the 
Diamond Princess cruise ship up to March 5, 2020, 
although it is slightly above the upper 95% confidence 
limit of the age-adjusted infection fatality ratio observed 
by March 25 (of 712 confirmed cases, 601 have been 
discharged, ten have died, and 11 remain in a critical 
condition). This difference might be due to repatriation 
flight data slightly underestimating milder infections, or 
due to cruise passengers having better outcomes because 
of a potentially higher-than-average quality of health care. 
Our estimates of the probability of requiring hospi-
talisation assume that only severe cases require hospi-
talisation. This assumption is clearly different from the 
pattern of hospitalisation that occurred in China, where 
hospitalisation was also used to ensure case isolation. 
Mortality can also be expected to vary with the underlying 
health of specific populations, given that the risks 
associated with COVID-19 will be heavily influenced by 
the presence of underlying comorbidities.
Our estimate of the case fatality ratio is substantially 
lower than the crude case fatality ratio obtained from 
China based on the cases and deaths observed to date, 
which is currently 3·67%, as well as many of the 
estimates currently in the literature. The principle reason 
for this difference is that the crude estimate does not take 
into account the severity of cases. For example, various 
estimates have been made from patient populations 
ranging from those with generally milder symptoms 
(for example international travellers detected through 
screening of travel history)13 through to those identified 
in the hospital setting.14,15
It is clear from the data that have emerged from China 
that case fatality ratio increases substantially with age. 
Our results suggest a very low fatality ratio in those 
under the age of 20 years. As there are very few cases in 
this age group, it remains unclear whether this reflects a 
low risk of death or a difference in susceptibility, although 
early results indicate young people are not at lower risk 
of infection than adults.28 Serological testing in this age 
group will be crucial in the coming weeks to understand 
the significance of this age group in driving population 
transmission. The estimated increase in severity with age 
is clearly reflected in case reports, in which the mean age 
tends to be in the range of 50–60 years. Different 
surveillance systems will pick up a different age case 
mix, and we find that those with milder symptoms 
detected through a history of travel are younger on 
average than those detected through hospital surveillance. 
Our correction for this surveillance bias therefore allows 
us to obtain estimates that can be applied to different 
case mixes and demographic population structures. 
However, it should be noted that this correction is 
applicable under the assumption of a uniform infection 
attack rate (ie, exposure) across the population. We also 
assumed perfect case ascertainment outside of Wuhan in 
the age group with the most cases relative to their 
population size (50–59-year-olds); however, if many cases 
were missed, the case fatality ratio and infection fatality 
ratio estimates might be lower. In the absence of random 
population surveys of infection prevalence, our adjust-
ment from case fatality ratio to infection fatality ratio 
relied on repatriation flight data, which was not age 
specific. The reported proportion of infected individuals 
who were asymptomatic on the Diamond Princess did not 
vary considerably by age, supporting this approach, but 
future larger representative population prevalence 
surveys and seroprevalence surveys will inform such 
estimates further.
Much of the data informing global estimates of the 
case fatality ratio at present are from the early outbreak 
in Wuhan. Given that the health system in this city was 
quickly overwhelmed, our estimates suggest that there is 
substantial under-ascertainment of cases in the younger 
age groups (who we estimate to have milder disease) by 
comparison with elsewhere in mainland China. This 
under-ascertainment is the main factor driving the 
difference between our estimate of the crude case fatality 
ratio from China (3·67%) and our best estimate of the 
overall case fatality ratio (1·38%). The case fatality ratio is 
likely to be strongly influenced by the availability of 
health-care facilities. However surprisingly, although 
health-care availability in Wuhan was stretched, our 
estimates from international cases are of a similar 
magnitude, suggesting relatively little difference in 
health outcome. Finally, as clinical knowledge of this new 
disease accrues, it is possible that outcomes will improve. 
It will therefore be impor tant to revise these estimates as 
epidemics unfold.
The world is currently experiencing the early stages of 
a global pandemic. Although China has succeeded in 
containing the disease spread for 2 months, such 
containment is unlikely to be achievable in most 
countries. Thus, much of the world will experience 
very large community epidemics of COVID-19 over the 
coming weeks and months. Our estimates of the 
underlying infection fatality ratio of this virus will inform 
assessments of health effects likely to be experienced in 
different countries, and thus decisions around appro-
priate mitigation policies to be adopted.
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